The Prognostic Value and Immune Landscapes of a m6A/m5C/m1A-Related LncRNAs Signature in Head and Neck Squamous Cell Carcinoma
Enhao Wang, Yang Li, Ruijie Ming, Jiahui Wei, Peiyu Du, Peng Zhou, Shimin Zong, Hongjun Xiao
Abstract
Background: N6-methyladenosine (m 6 A), 5-methylcytosine (m 5 C) and N1-methyladenosine (m 1 A) are the main RNA methylation modifications involved in the progression of cancer. However, it is still unclear whether m 6 A/m 5 C/m 1 A-related long non-coding RNAs (lncRNAs) affect the prognosis of head and neck squamous cell carcinoma (HNSCC). Methods: We summarized 52 m 6 A/m 5 C/m 1 A-related genes, downloaded 44 normal samples and 501 HNSCC tumor samples with RNA-seq data and clinical information from The Cancer Genome Atlas (TCGA) database, and then searched for m 6 A/m 5 C/m 1 A-related genes co-expressed lncRNAs. We adopt the least absolute shrinkage and selection operator (LASSO) Cox regression to obtain m 6 A/m 5 C/m 1 A-related lncRNAs to construct a prognostic signature of HNSCC. Results: This prognostic signature is based on six m 6 A/m 5 C/m 1 A-related lncRNAs (AL035587.1, AC009121.3, AF131215.5, FMR1-IT1, AC106820.5, PTOV1-AS2). It was found that the high-risk subgroup has worse overall survival (OS) than the low-risk subgroup. Moreover, the results showed that most immune checkpoint genes were significantly different between the two risk groups ( p < 0.05). Immunity microenvironment analysis showed that the contents of NK cell resting, macrophages M2, and neutrophils in samples of low-risk group were significantly lower than those of high-risk group ( p < 0.05), while the contents of B cells navie, plasma cells, and T cells regulatory (Tregs) were on the contrary ( p < 0.05). In addition, patients with high tumor mutational burden (TMB) had the worse overall survival than those with low tumor mutational burden. Conclusion: Our study elucidated how m 6 A/m 5 C/m 1 A-related lncRNAs are related to the prognosis, immune microenvironment, and TMB of HNSCC. In the future, these m 6 A/m 5 C/m 1 A-related lncRNAs may become a new choice for immunotherapy of HNSCC.